Dr. Peter Gross
Claim this profileHamilton Health Sciences, Juravinski Hospital
Studies Deep Vein Thrombosis
Studies Intrapericardial Thrombosis
4 reported clinical trials
7 drugs studied
Affiliated Hospitals
Clinical Trials Peter Gross is currently running
Statins
for Blood Clots
The standard or usual treatment for patients diagnosed with deep vein thrombosis or pulmonary embolism is treatment with blood thinners (called anticoagulants). While treatment of blood clots with blood thinners is effective, some research has shown that adding a statin (medication used to lower cholesterol) may give extra protection. It is thought that statins can improve how cells along the walls of the vein control inflammation, which can prevent new blood clots from forming. The medication in this study, rosuvastatin, is approved in Canada for use as a cholesterol-lowering medication. The use of rosuvastatin in this study is considered investigational. This means that Health Canada has not approved the use of rosuvastatin as a treatment for blood clots. However, it has been approved for use in this research study. The purpose of this study is to examine if adding a statin (rosuvastatin) to the usual blood thinner treatment will decrease the risk of another blood clot forming. The investigators also hope to discover if taking a statin reduces damage to your veins. To do this, some of the participants in this study will get rosuvastatin and others will receive a placebo (a substance that looks like the study rosuvastatin but does not have any active or medicinal ingredients). The placebo in this study is not intended to have any effect on your blood clot. A placebo is used to make the results of the study more reliable.
Recruiting1 award Phase 31 criteria
Abelacimab vs Apixaban
for Cancer-Related Blood Clots
This trial is testing abelacimab, a medication, to prevent blood clots in cancer patients who have had previous clots. It aims to see if it works better and causes fewer bleeding problems compared to a current treatment.
Recruiting2 awards Phase 36 criteria
More about Peter Gross
Clinical Trial Related1 year of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Peter Gross has experience with
- Rivaroxaban
- Tinzaparin
- Abelacimab
- Apixaban
- REGN9933
- Placebo Oral Tablet
Breakdown of trials Peter Gross has run
Deep Vein Thrombosis
Intrapericardial Thrombosis
Arterial Thromboembolic Disease
Venous Thromboembolism
Venous Stasis Syndrome
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Peter Gross specialize in?
Peter Gross focuses on Deep Vein Thrombosis and Intrapericardial Thrombosis. In particular, much of their work with Deep Vein Thrombosis has involved treating patients, or patients who are undergoing treatment.
Is Peter Gross currently recruiting for clinical trials?
Yes, Peter Gross is currently recruiting for 2 clinical trials in Hamilton Ontario. If you're interested in participating, you should apply.
Are there any treatments that Peter Gross has studied deeply?
Yes, Peter Gross has studied treatments such as Rivaroxaban, Tinzaparin, Abelacimab.
What is the best way to schedule an appointment with Peter Gross?
Apply for one of the trials that Peter Gross is conducting.
What is the office address of Peter Gross?
The office of Peter Gross is located at: Hamilton Health Sciences, Juravinski Hospital, Hamilton, Ontario L8V 1C3 Canada. This is the address for their practice at the Hamilton Health Sciences, Juravinski Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.